Abstract: A bearing bush of a turbocharger for radially mounting a shaft of the turbocharger. The bearing bush on an inner surface facing the shaft to be mounted, which forms a running surface of the bearing bush, has a microstructuring of multiple cup-shaped recesses at least in sections. The recesses have a maximum depth.

Abstract: A rotary joint includes an inner joint element which has a spherically shaped inner convex joint face and an inner joint connection head protruding from the inner convex joint face; an outer joint element which has a spherically shaped inner concave joint face, a spherically shaped outer convex joint face and an outer joint connection head protruding from the outer convex joint face, wherein the inner joint element is held within the outer joint element such that the two joint elements can be rotated with respect to one another along the inner joint faces; and a joint bearing which has a spherically shaped outer concave joint face, wherein the outer joint element is held within the joint bearing such that the outer joint element can be rotated in the joint bearing along the outer joint faces.

Abstract: A turbocharger, with a turbine and compressor housing connected to a bearing housing. An inflow housing of the turbine and bearing housing are connected via a fastening device mounted to a flange of the inflow housing with a first section and partially overlaps a flange of the bearing housing with a second section. Between the inflow housing and the bearing housing, flanges of a nozzle ring and of a sealing cover are clamped. Adjoining surfaces contacting one another in a region of a first, second, and/or a third contact clamping region are hardened.

Abstract: The present invention relates to the technical field of ionizing a gaseous substance, in particular the ionizing or ionization of a gaseous substance in preparation for its analysis. A device is intended to make a discharge gas and a test substance ionizable in a flow-through mode without essentially destroying or fragmenting the sample substance. In order to avoid a high expenditure in terms of construction and equipment, the device is intended to be usable under ambient conditions and to ensure a high sensitivity in a possible analysis of an ionized substance. To this end, an ionizing device is used for flow-through ionization of a discharge gas and of a sample substance at an absolute pressure of more than 40 kPa in the ionizing device during ionization. The ionizing device comprises an inlet, an outlet, a first electrode, a dielectric element and a second electrode.

Abstract: The present application relates to a process for removing an organic compound having one or more positive charges from an aqueous solution, comprising the steps a) provision of the aqueous solution comprising the organic compound and of a hydrophobic organic solution which comprises a liquid cation exchanger, where the liquid cation exchanger is hydrophobic, and where the liquid cation exchanger has one or more negative charges and an overall negative charge, b) contacting the aqueous solution and the organic solution, and c) separating off the organic solution from the aqueous solution.

Abstract: A device and a method for influencing a dynamic property of at least one movably mounted body of two bodies coupled mechanically at least via a variably adjustable stiffness along a first force path. The invention includes a damping element with constant damping properties directly or indirectly coupled in series with the variably adjustable stiffness along the first force path Both bodies are mechanically directly or indirectly coupled via a second force path running parallel to the first force path along which at least one adjustable stiffness is incorporated. The damping property of the damping element and the adjustable stiffnesses are coordinated and configured so that a damping property assigned to the device for mechanical coupling can be varied exclusively by the adjustable stiffnesses.

Abstract: The invention relates to a method for oxidizing an alkane, comprising contacting the alkane with a type alkB oxidoreductase and using a type alkB oxidoreductase to prepare a mixture of oxidation products of an alkane, wherein the ratio of carboxylic acid to alcohol in the oxidation products is preferably greater than 1:1.

Abstract: A turbocharger, has a turbine for expanding a first medium and a compressor for compressing a second medium. The turbine includes a turbine housing and a turbine rotor. The compressor includes a compressor housing and a compressor rotor coupled to the turbine rotor via a shaft. A bearing housing is arranged between the compressor and turbine housings in which the shaft is mounted. The turbine and bearing housings are connected via a fastening device mounted on a flange of the turbine housing with a first section and a second section that covers a flange of the bearing housing at least in sections. The fastening device is contoured curved on a surface of the second section facing the flange of the bearing housing.

Abstract: The present invention relates to a method for controlling a lighting device, the method comprising: receiving data relating to settings on a camera; determining an illuminance for at least one lighting device in dependence on said data; and modifying the illuminance of a lighting device to said determined illuminance.

Abstract: For characterizing spatial-temporal dynamics of a medium (1) excitable for deformation, an elastic model of the medium is defined. The medium is imaged at consecutive points in time to obtain a series of images. Shifts of structures of the medium (1) between the images of the series are determined. A dynamic description of a temporal development of spatial deformations of a predefined elastic model of the medium (1) is adapted to match the shifts of the structures; and temporal developments of rate of deformation patterns in the medium (1) are identified from the dynamic description.

Abstract: The present invention relates to the field of biology and medicine, and more specifically, to the field of stem-cell biology, involving producing or generating melanocytes from stem-cells and precursors derived from human hair root. Additionally, the present invention relates to the materials and method for producing autografts, homografts or allografts comprising melanocytes in general, as well as the materials and methods for producing autografts, homografts and allografts comprising melanocytes for the treatment of diseases related to depigmentation of the skin and for the treatment of scars.

Abstract: A process for producing alanine, including culturing a cell under aerobic conditions in an aqueous phase in the presence of an inorganic nitrogen source, and then contacting the aqueous phase and the cell cultured in the aqueous phase with a hydrophobic organic phase. The cell is a prokaryotic or a lower eukaryotic cell and expresses a recombinant alanine dehydrogenase.

Abstract: The invention relates to curable compositions comprising at least one epoxy resin and at least one hardener wherein the hardener is a compound of formula (I) or (II) where R1 and R2 are each independently selected from the group of substituents having the formula —(CH2)x—NH2 and x is in each case independently 0, 1, 2, 3 or 4, to surfaces comprising such compositions, to methods comprising applying a coating material comprising such compositions and to the use of such compositions as surface protection.

Abstract: The invention relates to a dosage form that is suitable for releasing an active ingredient over a long period of time. For this purpose, the active ingredient is released in two-stages in order to do away with an excessively frequent ingestion of the dosage form. The dosage forms according to the invention are for treating dizziness in humans. They are administered with or after a meal. The concept according to the invention provides that the pharmaceutical form has a dimensionally stable portion which, after ingestion of the dosage form by the patients, does not dissolve in the chyme-filled stomach for a number of hours. In this way, this dimensionally stable portion remains in the stomach until same is evacuated by the so-called “housekeeper waves”. Another portion of the dosage form is formed in such a way that it dissolves within a short time of the patients ingesting same. In this way, a quick invasion of the active ingredient with corresponding plasma levels is ensured.

Abstract: The invention relates to a method for oxidizing a fatty acid or an ester thereof of formula (I) H3C —(CH2)n-COOR, wherein R is selected from the group that comprises H, methyl, ethyl, propyl, and butyl, wherein n is 0 to 30, preferably 6 to 24, comprising the step of oxidizing the fatty acid or the ester thereof by contacting the fatty acid or the ester thereof with a cytochrome P450 monooxygenase of the CYP153 family in the presence of molecular oxygen and NAD(P)H and a whole-cell catalyst that expresses a recombinant cytochrome P450 monooxygenase of the CYP153 family, a recombinant alcohol dehydrogenase, a recombinant transaminase, and optionally one or more than one recombinant enzyme from the group comprising alanine dehydrogenase, ferredoxin, and ferredoxin reductase, and the use of said whole-cell catalyst to oxidize a fatty acid or an ester thereof.

Abstract: A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.

Abstract: A method including the steps a) providing a primary alcohol of the formula HO—(CH2)x—R1, where R1 is —OH, —SH, —NH2 or —COOR2; x is at least 3; and R2 is H, alkyl or aryl, b) oxidizing the primary alcohol by contacting it with an NAD(P)+-dependent alcohol dehydrogenase, and c) contacting the oxidation product of step a) with a transaminase, where the NAD(P)+-alcohol dehydrogenase and/or the transaminase is a recombinant or isolated enzyme. A whole cell catalyst for carrying out the method. The use of such a whole cell catalyst for oxidizing a primary alcohol.

Abstract: A supply network for supplying consumers with a medium is provided. Based on a reduction of data and a subsequent reconstruction of at least one pressure and/or flow value, the state at least at one further location in the supply network can be determined without having to be measured. An improved actuation of the at least one pump and/or of the at least one valve is thus possible. A device for pressure control in a supply network is also provided.

Abstract: A rear area monitoring device for a vehicle includes one or more distance sensors configured to determine the distance of the rear of the vehicle from an obstacle, and at least one electronic control device configured to evaluate the data collected by the distance sensor(s) and to determine a distance signal that indicates the current distance of the rear of the vehicle from the obstacle. The electronic control device includes at least one input connection for a position sensor configured to detect the position of at least one adjustable vehicle component that, in certain positions, projects beyond the rear of the vehicle. The electronic control device is configured to determine the distance signal depending upon the signal of the position sensor.

Abstract: A method predicts the residual risk of recurrence after a taxane-free chemotherapy, and the benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent breast cancer. From determination of expression levels of the genes UBE2C, KIF20A, PTGER3, OSBPL1A, CYP27A1, IGKC, in a tumor sample a prognostic score is determined by mathematically combining the expression level values. The prognostic score is compared to thresholds, classifying the patient in three outcome groups. The expression levels of three genes STC1, PCSK6, S100P in the tumor sample are determined, and the expression level values for STC1, PCSK6 and S100P are mathematically combined to yield a predictive combined score, whereas a high predictive combined score generally indicates an increased likelihood of benefit from inclusion of taxane in a chemotherapy regimen in a patient classified to poor and/or intermediate outcome group.